Results 1 to 10 of about 2,024 (91)
Some of the next articles are maybe not open access.
Hospital Pharmacy, 2021
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Terri L. Levien, Danial E. Baker
openaire +3 more sources
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Terri L. Levien, Danial E. Baker
openaire +3 more sources
Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns
Clinical Microbiology and Infection, 2021François Montastruc +2 more
exaly
Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis
Clinical Microbiology and Infection, 2022Guillaume Butler-Laporte +2 more
exaly
Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care
Clinical Infectious Diseases, 2021Robert L Gottlieb +2 more
exaly
Remdesivir and systemic corticosteroids for the treatment of COVID-19: A Bayesian re-analysis
International Journal of Infectious Diseases, 2021Guillaume Butler-Laporte +2 more
exaly
A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir
European Journal of Medicinal Chemistry, 2020Chengyuan Liang, Lei Tian, Xu Zhao
exaly
Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies
Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020Awadhesh Singh, Ritu Singh
exaly
Effect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials
Virus Research, 2020Yujiro Yokoyama +2 more
exaly